Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Board Appointment

25 Nov 2014 07:00

RNS Number : 8702X
Byotrol PLC
25 November 2014
 



 

25 November 2014

 

Byotrol plc

BOARD APPOINTMENT

 

Byotrol plc ("Byotrol" or "the company", the leading AIM listed anti-microbial hygiene company, today announces the appointment of Dr Trevor Francis to its board as Chief Technology Officer with immediate effect.

 

Dr Francis has been working as a consultant to the Company in various positions over the last six years, particularly in consumer product development and commercialisation. Prior to joining Byotrol, Dr Francis spent 29 years at Unilever where he became Vice President of the Global R&D Homecare division and Head of the European Fabric Conditioners & Global Fragrance divisions.

 

Dr Francis is also a board trustee of the Liverpool School of Tropical Medicine where he serves on the Audit and Remuneration Committees.

 

Commenting on the appointment, Nicholas Martel, Chairman of Byotrol, said:

 

"We are delighted to welcome Trevor to the Board. His proven experience of delivering innovative products to market will be invaluable as we seek to consolidate on the recent improvements made within the Company."

 

The following information in relation to the appointment of Dr Francis is disclosed pursuant to Schedule 2(g) of the AIM Rules for Companies:

 

Full Name: Dr Thomas Trevor Francis

Age: 64

 

Current Directorships and Partnerships

Directorships and Partnerships held in the last five years

Tecnoform Associates Limited

None

Liverpool School of Tropical Medicine

 

Shareholding in Company

Options held over Company Shares

% Shareholding in Company post option exercise

Trevor Francis

739,846

2,250,000

1.33%

 

Dr Francis does not have a cash bonus scheme for the financial year ending 31 March 2015.

 

The options for Dr Francis have been granted in the Company's Enterprise Management Incentive Scheme.

 

There are no other matters which are required to be disclosed pursuant to Schedule 2(g) of the AIM Rules for Companies.

 

Enquiries:

 

Byotrol plc

01925 742 000

David Traynor - Chief Executive

Dawn Williams - Group Marketing Controller

 

 

finnCap Ltd

020 7220 0500

Geoff Nash

Christopher Raggett

 

 

 

Notes to Editors:

 

Byotrol plc (BYOT.L), quoted on AIM, is a leading anti-microbial technology company, operating globally in the Food, Industrial, Healthcare and Consumer sectors, providing low toxicity products with a broad-based and long-lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, mycobacteria and algae.

Powerful, long-lasting and gentle, Byotrol's products can be used stand alone or as an ingredient within existing products, where Byotrol can significantly improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Founded in 2005, the Company has developed the technology that creates easier, safer and cleaner lives for everyone.

 

For more information, please go to www.byotrol.co.uk 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPGGMCGUPCGRC
Date   Source Headline
1st Nov 202111:36 amRNSTotal Voting Rights
1st Nov 202111:20 amRNSHolding(s) in Company
28th Oct 202111:40 amRNSExercise of Options & Total Voting Rights
20th Oct 20214:46 pmRNSResult of AGM
1st Oct 20217:00 amRNSSale of Byotrol24 in the Americas
27th Sep 20214:36 pmRNSPosting of Annual Report & Accounts/Notice of AGM
1st Sep 20217:00 amRNSInvestor Presentation
20th Aug 202110:01 amRNSHolding(s) in Company
19th Aug 20217:00 amRNSFinal Results
27th Jul 20217:00 amRNSNotice of Results
21st Jun 20217:00 amRNSAlcohol-free Hand Sanitisers Backed by TIGGR
28th Apr 20219:47 amRNSExercise of Options & Total Voting Rights
27th Apr 20217:00 amRNSHolding(s) in Company
22nd Apr 20212:05 pmRNSSecond Price Monitoring Extn
22nd Apr 20212:00 pmRNSPrice Monitoring Extension
22nd Apr 20217:00 amRNSTrading Update
16th Apr 20214:40 pmRNSHolding(s) in Company
26th Feb 20217:00 amRNSTest Protocol for Testing Anti-Viral Efficacy
21st Jan 202110:30 amRNSExercise of Options & Total Voting Rights
8th Jan 20219:36 amRNSCapital reduction
21st Dec 20208:26 amRNSHolding(s) in Company
7th Dec 20207:00 amRNSInterim Results
13th Nov 202011:30 amRNSResult of AGM
13th Nov 20207:00 amRNSAGM Statement
6th Nov 202011:27 amRNSAnnual General Meeting – update on arrangements
20th Oct 20201:42 pmRNSPosting of circular & notice of AGM
14th Oct 20204:30 pmRNSExercise of Options & Total Voting Rights
13th Oct 202011:09 amRNSPUBLICATION OF AUDITED RESULTS
25th Sep 20207:00 amRNSDirector Dealing
25th Sep 20207:00 amRNSInvestor Presentation
24th Sep 20207:00 amRNSPreliminary Results
7th Sep 20207:00 amRNSGrant Award
27th Aug 20208:07 amRNSHolding(s) in Company
20th Aug 20208:10 amRNSHolding(s) in Company
18th Aug 20205:01 pmRNSHolding(s) in Company
18th Aug 20204:42 pmRNSSecond Price Monitoring Extn
18th Aug 20204:36 pmRNSPrice Monitoring Extension
17th Aug 20209:05 amRNSSecond Price Monitoring Extn
17th Aug 20209:00 amRNSPrice Monitoring Extension
3rd Aug 20207:00 amRNSTrading Update
16th Jul 20202:40 pmRNSHolding(s) in Company
3rd Jul 20207:00 amRNSExercise of Options and Total Voting Rights
29th Jun 20204:29 pmRNSHolding(s) in Company
19th May 202012:08 pmRNSHolding(s) in Company
14th May 20207:00 amRNSLicense Agreements and Update on Trading
27th Apr 20207:30 amRNSTrading Update
22nd Apr 20204:41 pmRNSSecond Price Monitoring Extn
22nd Apr 20204:36 pmRNSPrice Monitoring Extension
8th Apr 20207:00 amRNSHolding(s) in Company
6th Apr 202011:26 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.